Belite Bio

BLTE · NASDAQ

$154.45+$7.11 (+4.83%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $147.34

BLTE analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $233.47 (+51.2% upside)

Low: $186.85
Now: $154.45
High: $318.15

Upgrades and downgrades

The latest rating actions, newest first

BLTE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 15, 2026	Maintains	Buy	$245.00	40%
Mizuho	Sep 9, 2026	Maintains	Outperform	$220.00 → $234.00	54%
HC Wainwright & Co.	Sep 8, 2026	Maintains	Buy	$214.00 → $245.00	40%
Canaccord Genuity	Sep 4, 2026	Initiates	Buy	$303.00	41%
Morgan Stanley	Aug 14, 2026	Maintains	Overweight	$201.00 → $206.00	57%
Cantor Fitzgerald	Aug 14, 2026	Maintains	Overweight	$266.00 → $270.00	39%
HC Wainwright & Co.	Aug 12, 2026	Maintains	Buy	$200.00 → $214.00	40%
HC Wainwright & Co.	Jun 15, 2026	Maintains	Buy	$200.00	40%
Mizuho	May 26, 2026	Maintains	Outperform	$223.00 → $215.00	54%
HC Wainwright & Co.	May 21, 2026	Maintains	Buy	$200.00	40%

The case for and against

Updated Oct 14, 2026

Bull case

Belite Bio is compelling because tinlarebant has generated clinically meaningful Phase 3 efficacy in Stargardt disease, including a 36% reduction in retinal lesion growth and sustained RBP4 suppression of about 80%, while remaining well tolerated in studies. The regulatory backdrop is similarly strong, with FDA Priority Review and a February 12, 2027 PDUFA date, Japan’s SAKIGAKE designation and NDA submission, and additional filings or acceptances in the U.K. and China, which support a clear path to commercialization. Financially, the company ended 2Q26 with $279.9 million in cash and equivalents plus $500.1 million in U.S. treasury bills/notes, while the combination of rare-disease unmet need, no approved therapies, and a second Phase 3 program in GA gives the stock multiple fundamental catalysts.

Bear case

Belite Bio is a clinical-stage company with no approved products, so its investment case hinges on tinlarebant clearing regulatory, clinical, and commercial hurdles that remain highly uncertain. The company faces the possibility of additional clinical testing, changing agency requirements, or outright non-approval in the US, China, and UK, while also contending with launch uncertainty in Stargardt disease and a competitive GA market already served by Syfovre and Izervay. Financially, the risk is amplified by a challenging biotechnology funding environment, and even the cited 24-month STGD1 data—42% of treated subjects with no incident atrophic lesions and stable to slightly decreased qAF at Month 25—does not eliminate safety, efficacy, or financing concerns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.